Philips said the latest tests indicated that exposure to particulate matter emissions from degraded foam in DreamStation devices was “unlikely to result in an appreciable harm to health in patients”, provided the machines had not been treated with ozone-based cleansing products.
Featured Posts
BioTelemetry Inc. and its subsidiary CardioNet LLC have reached a settlement over allegations that they knowingly submitted claims to Medicare, TRICARE, the Veterans Health Administration and the Federal Employee Health Benefits Program for heart monitoring tests that were performed, in part, outside the United States.
Entrada Therapeutics said it received a clinical hold notice from the regulatory agency but no reason was provided. “We are eager to resolve this hold and continue down the treatment development pathway,” President and CEO Dipal Doshi said.
Kroger joins pharmacy chains CVS Health Corp and Walgreens Boots Alliance Inc., which have also limited purchases of children’s pain medicines at a time when U.S. flu hospitalizations have jumped to the highest in a decade for this time of year.
The job cuts will span three business units – Novartis Pharmaceuticals, Novartis Services Inc., and Novartis Corporation – with terminations taking effect on January 28, 2023.
The year 2022 was relatively thin for pharma M&A, with deals worth nearly $66 billion being announced by early December. However, drugmakers are primed for a shopping spree in 2023.
A parliamentary committee said that India-based drug maker Maiden Pharmaceuticals Ltd was responsible for the deaths of at least 70 children from acute kidney injury and called on the government to pursue legal action.
Six months after the U.S. Supreme Court overturned its 1973 Roe v. Wade ruling, the state of abortion rights around the country remains unsettled, thanks to a patchwork of lawsuits in state courts and emergency court orders.
Bushu Pharma, established in 1998, is one of the leading manufacturers of pharmaceutical and medical devices in Japan.
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.